Guardian Pharmacy Services, Inc. (GRDN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Guardian Pharmacy Services, Inc. stock (GRDN) is currently trading at $37.57. Guardian Pharmacy Services, Inc. PE ratio is 48.17. Guardian Pharmacy Services, Inc. PS ratio (Price-to-Sales) is 1.67. Analyst consensus price target for GRDN is $38.50. WallStSmart rates GRDN as Underperform.
- GRDN PE ratio analysis and historical PE chart
- GRDN PS ratio (Price-to-Sales) history and trend
- GRDN intrinsic value — DCF, Graham Number, EPV models
- GRDN stock price prediction 2025 2026 2027 2028 2029 2030
- GRDN fair value vs current price
- GRDN insider transactions and insider buying
- Is GRDN undervalued or overvalued?
- Guardian Pharmacy Services, Inc. financial analysis — revenue, earnings, cash flow
- GRDN Piotroski F-Score and Altman Z-Score
- GRDN analyst price target and Smart Rating
Guardian Pharmacy Services, Inc.
📊 No data available
Try selecting a different time range
GRDN Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Guardian Pharmacy Services, Inc. (GRDN)
GRDN trades 553% above its Graham fair value of $5.30, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Guardian Pharmacy Services, Inc. (GRDN) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, price/sales, institutional own.. Concerns around operating margin and price/book. Mixed signals suggest waiting for clearer direction before acting.
Guardian Pharmacy Services, Inc. (GRDN) Key Strengths (4)
Every $100 of shareholder equity generates $27 in profit
Paying $1.67 for every $1 of annual revenue
57.25% held by institutions, strong professional interest
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Guardian Pharmacy Services, Inc. (GRDN) Areas to Watch (4)
Very thin margins with limited operational efficiency
Very expensive at 11.0x book value
Very thin margins, barely profitable
Solid revenue growth at 17.40% per year
Supporting Valuation Data
Guardian Pharmacy Services, Inc. (GRDN) Detailed Analysis Report
Overall Assessment
This company scores 44/100 in our Smart Analysis, earning a D grade. Out of 8 metrics analyzed, 4 register as strengths (avg 8.3/10) while 4 fall into concern territory (avg 3.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Price/Sales, Institutional Own.. Valuation metrics including Price/Sales (1.67) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 26.60%.
The Bear Case
The primary concerns are Operating Margin, Price/Book, Profit Margin. Some valuation metrics including Price/Book (10.96) suggest expensive pricing. Growth concerns include Revenue Growth at 17.40%, which may limit upside. Profitability pressure is visible in Operating Margin at 8.90%, Profit Margin at 3.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 26.60% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 17.40% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Price/Book are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
GRDN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
GRDN's Price-to-Sales ratio of 1.67x trades 72% above its historical average of 0.97x (96th percentile), historically expensive. The current valuation is 0% below its historical high of 1.67x set in Mar 2026, and 183% above its historical low of 0.59x in Feb 2025. Over the past 12 months, the PS ratio has expanded from ~0.6x, reflecting growing market expectations outpacing revenue growth.
Compare GRDN with Competitors
Top MEDICAL CARE FACILITIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Guardian Pharmacy Services, Inc. (GRDN) · HEALTHCARE › MEDICAL CARE FACILITIES
The Big Picture
Guardian Pharmacy Services, Inc. is a strong growth company balancing expansion with improving profitability. Revenue reached 1.4B with 17% growth year-over-year. Profit margins are strong at 340.0%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 2660.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 30M in free cash flow and 35M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Sector dynamics: monitor MEDICAL CARE FACILITIES industry trends, competitive moves, and regulatory changes that could impact Guardian Pharmacy Services, Inc..
Bottom Line
Guardian Pharmacy Services, Inc. offers an attractive blend of growth (17% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Guardian Pharmacy Services, Inc.(GRDN)
NYSE
HEALTHCARE
MEDICAL CARE FACILITIES
USA
Guardian Pharmacy Services, Inc. is a leading provider of specialized pharmacy solutions for the long-term care sector, which includes assisted living and skilled nursing facilities. The company is distinguished by its commitment to personalized medication management, ensuring high standards of quality and compliance while delivering exceptional customer service. Leveraging advanced technology and deep pharmaceutical expertise, Guardian aims to enhance patient outcomes and streamline workflows for its healthcare partners. With a strong operational presence across multiple states, the company is well-positioned to address the growing needs for tailored pharmacy services amidst an evolving healthcare landscape.